Elizabeth Pabon Vazquez
Nephrology · Weston, FLNPI 1437643699
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $790 and has fallen 95.8% since, to $33 in 2025.
Across 70 payments — averaging $27.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$318
- Calliditas Therapeutics US Inc.$208
- Merck$152
- Travere Therapeutics, Inc.$131
- Fresenius USA Marketing, Inc.$122
- E.r. Squibb & Sons, L.L.C.$118
- plus $853 from 16 others
What the payments were for
- Food & beverage$1,86498%
- Education$382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $318 |
| Calliditas Therapeutics US Inc. | 3 | $208 |
| Merck | 2 | $152 |
| Travere Therapeutics, Inc. | 2 | $131 |
| Fresenius USA Marketing, Inc. | 6 | $122 |
| E.r. Squibb & Sons, L.L.C. | 5 | $118 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $102 |
| Aurinia Pharma U.S., Inc. | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Ardelyx, Inc. | 3 | $70 |
| Bayer | 3 | $66 |
| OPKO Pharmaceuticals, LLC | 3 | $64 |
| Johnson & Johnson | 3 | $58 |
| PBG Puerto Rico LLC | 3 | $50 |
| Chiesi USA, Inc. | 3 | $47 |
| GSK | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Veloxis Pharmaceuticals, Inc. | 1 | $33 |
| Amgen | 1 | $32 |
| Boehringer Ingelheim | 1 | $29 |
| Novartis | 1 | $22 |
| Amicus Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,903 in reported general payments places this provider in the 55th percentile of 756 nephrology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 14 | $79 |
| Furosemide | 17 | $71 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Weston
- John CopleyWeston$934K
- Arvind MadanOrlando$943K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.